SCHEMBL3533576

SCHEMBL3533576

CN1CCN(c2ccc3nc(-c4n[nH]c5cccc(N)c45)[nH]c3c2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.71
FLT1 P17948 6/20 0.71
PDGFRB P09619 7/20 0.57
KDR P35968 7/20 0.57
FLT3 P36888 2/20 0.56
CDK4 P11802 2/20 0.56
PDPK1 O15530 2/20 0.56
PLK4 O00444 1/20 0.56
STK25 O00506 1/20 0.56
CIT O14578 1/20 0.56
RIOK3 O14730 1/20 0.56
CHEK1 O14757 1/20 0.56
GAK O14976 1/20 0.56
CHUK O15111 1/20 0.56
MUSK O15146 1/20 0.56
EPHB6 O15197 1/20 0.56
MAP3K13 O43283 1/20 0.56
DAPK3 O43293 1/20 0.56
MAP3K7 O43318 1/20 0.56
NUAK1 O60285 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31006247 1.00 FGFR1 (0.71) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL29009530 0.89 FGFR1 (0.70) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL31006236 0.89 FGFR1 (0.70) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL3537272 0.86 FGFR1 (0.71) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL5866750 0.86 FGFR1 (0.71) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL3545063 0.86 FGFR1 (0.68) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL29009529 0.85 FGFR1 (0.73) FGFR1FLT1PDGFRBKDRPDPK1
SCHEMBL3533470 0.85 FGFR1 (0.73) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL3539715 0.84 FGFR1 (0.66) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL31006248 0.84 FGFR1 (0.65) FGFR1FLT1PDGFRBKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217551-A Substituted indazole or azaindazole compounds and application thereof 河南中医药大学 2023-06-06 CN disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885PDGFRB 1595/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885PDGFRB 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.